Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms (Q36696091)

15 August 2017

1 reference

title

Substance use disorders and Schizophrenia: a question of shared glutamatergic mechanisms (English)

1 reference

15 August 2017

1 reference

Joseph T Coyle

1

1 reference

15 August 2017

1 December 2006

1 reference

15 August 2017

13

1 reference

inferred from page(s)

published in

Neurotoxicity Research

1 reference

15 August 2017

10

1 reference

15 August 2017

3-4

1 reference

15 August 2017

221-233

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03033359

15 August 2017

0 references

cites work

Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

A single dominant gene can account for eye tracking dysfunctions and schizophrenia in offspring of discordant twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

The effect of acamprosate on the development of morphine-induced behavioral sensitization in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

Abnormal excitatory neurotransmitter metabolism in schizophrenic brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03033359

N-acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells

21 January 2018

1 reference

12 December 2020

D-serine added to clozapine for the treatment of schizophrenia

1 reference

12 December 2020

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

1 reference

12 December 2020

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

1 reference

12 December 2020

Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention.

1 reference

12 December 2020

Increased cortical kynurenate content in schizophrenia

1 reference

12 December 2020

Effect of Phencyclidine in Chronic Schizophrenics

1 reference

12 December 2020

Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia

1 reference

12 December 2020

Effect of catechol-O-methyltransferase val158met genotype on attentional control.

1 reference

12 December 2020

Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects.

1 reference

12 December 2020

NMDA-dependent modulation of CA1 local circuit inhibition.

1 reference

12 December 2020

Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies

1 reference

12 December 2020

Is there a common molecular pathway for addiction?

1 reference

12 December 2020

M50 sensory gating predicts negative symptoms in schizophrenia.

1 reference

12 December 2020

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

1 reference

12 December 2020

Genes for schizophrenia? Recent findings and their pathophysiological implications

1 reference

12 December 2020

Local acamprosate modulates dopamine release in the rat nucleus accumbens through NMDA receptors: an in vivo microdialysis study.

1 reference

12 December 2020

How does drug and alcohol misuse develop among people with psychotic illness? A literature review

1 reference

12 December 2020

Effects of D-cycloserine on negative symptoms in schizophrenia

1 reference

12 December 2020

Functional magnetic resonance imaging studies of schizophrenic patients during word production: effects of D-cycloserine

1 reference

12 December 2020

Atypical antipsychotics: mechanism of action.

1 reference

12 December 2020

Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia

1 reference

12 December 2020

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

12 December 2020

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

12 December 2020

The NMDA receptor channel blocker memantine and opioid receptor antagonist naltrexone inhibit the saccharin deprivation effect in rats

1 reference

12 December 2020

Hypoxic-ischemia-related fetal/neonatal complications and risk of schizophrenia and other nonaffective psychoses: a 19-year longitudinal study

1 reference

12 December 2020

Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence

1 reference

12 December 2020

The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

1 reference

12 December 2020

Cerebral ventricular change over the first 10 years after the onset of schizophrenia

1 reference

12 December 2020

Clozapine reduces alcohol drinking in Syrian golden hamsters

1 reference

12 December 2020

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear

1 reference

12 December 2020

MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes.

1 reference

12 December 2020

Significant interaction between clozapine and cocaine in cocaine addicts

1 reference

12 December 2020

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

12 December 2020

Substance misuse in patients with schizophrenia: epidemiology and management

1 reference

12 December 2020

A review of diffusion tensor imaging studies in schizophrenia

1 reference

12 December 2020

The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans

1 reference

12 December 2020

Effects of a novel uncompetitive NMDA receptor antagonist, MRZ 2/579 on ethanol self-administration and ethanol withdrawal seizures in the rat.

1 reference

12 December 2020

Memantine presents different effects from MK-801 in motivational and physical signs of morphine withdrawal.

1 reference

12 December 2020

Ketamine: an update on the first twenty-five years of clinical experience

1 reference

12 December 2020

Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities?

1 reference

12 December 2020

Functional significance of long-term potentiation for sequence learning and prediction.

1 reference

12 December 2020

Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder

1 reference

12 December 2020

GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder

1 reference

12 December 2020

Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia

1 reference

12 December 2020

Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation

1 reference

12 December 2020

Association of G72/G30 with schizophrenia in the Chinese population

1 reference

12 December 2020

Reduced hippocampal N-acetylaspartate without volume loss in schizophrenia.

1 reference

12 December 2020

Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden

1 reference

12 December 2020

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

1 reference

12 December 2020

Neuregulins: functions, forms, and signaling strategies

1 reference

12 December 2020

Support for involvement of neuregulin 1 in schizophrenia pathophysiology

1 reference

12 December 2020

Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain.

1 reference

12 December 2020

Is the G72/G30 locus associated with schizophrenia? single nucleotide polymorphisms, haplotypes, and gene expression analysis

1 reference

12 December 2020

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

12 December 2020

LTP may trigger addiction

1 reference

12 December 2020

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

1 reference

12 December 2020

NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons

1 reference

12 December 2020

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients

1 reference

12 December 2020

Finding schizophrenia genes

1 reference

12 December 2020

The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity

1 reference

12 December 2020

Comparative genome- and proteome analysis of cerebral cortex from MK-801-treated rats

1 reference

12 December 2020

Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series

1 reference

12 December 2020

Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder.

1 reference

12 December 2020

Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

12 December 2020

Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex.

1 reference

12 December 2020

Early-stage visual processing and cortical amplification deficits in schizophrenia

1 reference

12 December 2020

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

1 reference

12 December 2020

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

12 December 2020

A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics

1 reference

12 December 2020

Selective alterations in prefrontal cortical GABA neurotransmission in schizophrenia: a novel target for the treatment of working memory dysfunction

1 reference

12 December 2020

Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses.

1 reference

12 December 2020

NMDA receptor antagonists disinhibit rat posterior cingulate and retrosplenial cortices: a potential mechanism of neurotoxicity.

1 reference

12 December 2020

Placebo-controlled trial of glycine added to clozapine in schizophrenia

1 reference

12 December 2020

Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection

1 reference

12 December 2020

Study of a new schizophrenomimetic drug; sernyl.

1 reference

12 December 2020

Frontal lobe N-acetylaspartate correlates with psychopathology in schizophrenia: a proton magnetic resonance spectroscopy study

1 reference

12 December 2020

Findings in an independent sample support an association between bipolar affective disorder and the G72/G30 locus on chromosome 13q33

1 reference

12 December 2020

Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study

1 reference

12 December 2020

Effects of ketamine in normal and schizophrenic volunteers

1 reference

12 December 2020

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

12 December 2020

Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients

1 reference

12 December 2020

Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

1 reference

12 December 2020

Polymorphisms in the 13q33.2 gene G72/G30 are associated with childhood-onset schizophrenia and psychosis not otherwise specified.

1 reference

12 December 2020

Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo

1 reference

12 December 2020

NMDA receptors in alcoholism

1 reference

12 December 2020

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey

1 reference

12 December 2020

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

12 December 2020

[3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics

1 reference

12 December 2020

Interaction of acamprosate with ethanol and spermine on NMDA receptors in primary cultured neurons

1 reference

12 December 2020

Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone

1 reference

12 December 2020

N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability

1 reference

12 December 2020

The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective

1 reference

12 December 2020

Impaired P3 generation reflects high-level and progressive neurocognitive dysfunction in schizophrenia

1 reference

12 December 2020

Ionotropic glutamate receptors as therapeutic targets in schizophrenia

1 reference

12 December 2020

D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes.

1 reference

12 December 2020

Effect of systemic administration of D-serine on the levels of D- and L-serine in several brain areas and periphery of rat.

1 reference

12 December 2020

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.

1 reference

12 December 2020

Neuroimaging studies of the hippocampus in schizophrenia

1 reference

12 December 2020

A decrease of reelin expression as a putative vulnerability factor in schizophrenia

1 reference

12 December 2020

Concomitant clozapine reduces smoking in patients treated with risperidone

1 reference

12 December 2020

Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia

1 reference

12 December 2020

The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia

1 reference

12 December 2020

A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia

1 reference

12 December 2020

Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia

1 reference

12 December 2020

Transmission disequilibrium and haplotype analyses of the G72/G30 locus: Suggestive linkage to schizophrenia in Palestinian Arabs living in the North of Israel

1 reference

12 December 2020

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

1 reference

12 December 2020

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

12 December 2020

Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia

1 reference

12 December 2020

Evidence for abnormal cortical functional connectivity during working memory in schizophrenia

1 reference

12 December 2020

Endogenous kynurenic acid disrupts prepulse inhibition

1 reference

12 December 2020

Differential effects of atypical and typical antipsychotic drugs on N-methyl-D-aspartate- and electrically evoked responses in the pyramidal cells of the rat medial prefrontal cortex

1 reference

12 December 2020

Decoding neuronal firing and modelling neural networks

1 reference

12 December 2020

Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia

1 reference

12 December 2020

Dopamine receptors, neuroleptics, and schizophrenia

1 reference

12 December 2020

Functional comparison of D-serine and glycine in rodents: the effect on cloned NMDA receptors and the extracellular concentration.

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03033359

1 reference

15 August 2017

1 reference

PubMed ID

17197372